autologous anti-CD19 CAR T cells GC019F

{
  "id": "MLC-T-ONC-011354",
  "term": "autologous anti-CD19 CAR T cells GC019F",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T cells GC019F target and bind to CD19-expressing tumor cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the release of cytotoxic molecules and the induction of tumor cell lysis. CD19, cluster of differentiation 19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors. The processing platform used, FasTCAR, shortens the manufacturing time to produce the CAR T cells.",
  "synonyms": [
    "autologous CD19-targeted CAR T cells GC019F",
    "autologous FasTCAR-enabled CD19-targeted CAR T cells GC019F"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-anti-cd19-car-t-cells-gc019f/"
}